期刊文献+

Preliminary Evaluation of Safety of Conditionally Replication Adenovirus M4

Preliminary Evaluation of Safety of Conditionally Replication Adenovirus M4
下载PDF
导出
摘要 Conditionally replication adenovirus M4, which was constructed in our lab, was proved to have good clinical application prospect for its good antitumor and antimetastasis effect. However, clinically applying M4 faces many problems. One of the most important is the safety of M4. In this study, we investigated the safety of M4 by comparing with Adv-TK, which was proved to be safe in Ⅰ–Ⅲ phase clinical trials. M4 and Adv-TK were injected into mice via the tail vein separately, and the mice were sacrificed at the indicated time. Blood was collected for biochemical tests, the liver was harvested for hematoxylin and eosin (H&E) staining and viral quantification, and splenic lymphocytes were separated for adenovirus specific cellular immune response. Our results showed that M4 had no obvious effect on mouse general symptoms. A transient reversible infiltration of inflammatory cells in collect abbacy was only observed in M4 group, and a transient slight increase in Cr level was detected both after M4 and Adv-TK injection. The adenovirus specific cellular immune response induced by M4 was similar to that by Adv-TK, and the distribution and metabolism of M4 in the mouse liver were also similar to those of Adv-TK. It was concluded that conditionally replication adenovirus M4 had the same safety as Adv-TK. The study provides safety basis for the coming clinical trials of M4. Conditionally replication adenovirus M4, which was constructed in our lab, was proved to have good clinical application prospect for its good antitumor and antimetastasis effect. However, clinically applying M4 faces many problems. One of the most important is the safety of M4. In this study, we investigated the safety of M4 by comparing with Adv-TK, which was proved to be safe in Ⅰ–Ⅲ phase clinical trials. M4 and Adv-TK were injected into mice via the tail vein separately, and the mice were sacrificed at the indicated time. Blood was collected for biochemical tests, the liver was harvested for hematoxylin and eosin (H&E) staining and viral quantification, and splenic lymphocytes were separated for adenovirus specific cellular immune response. Our results showed that M4 had no obvious effect on mouse general symptoms. A transient reversible infiltration of inflammatory cells in collect abbacy was only observed in M4 group, and a transient slight increase in Cr level was detected both after M4 and Adv-TK injection. The adenovirus specific cellular immune response induced by M4 was similar to that by Adv-TK, and the distribution and metabolism of M4 in the mouse liver were also similar to those of Adv-TK. It was concluded that conditionally replication adenovirus M4 had the same safety as Adv-TK. The study provides safety basis for the coming clinical trials of M4.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2012年第6期893-898,共6页 华中科技大学学报(医学英德文版)
基金 supported by grants from National Natural Science Foundation of China(No.81072135) the "973" Program of China (No.2009CB521800)
关键词 conditionally replication adenovirus M4 SAFETY blood biochemistry DISTRIBUTION conditionally replication adenovirus M4 safety blood biochemistry distribution
  • 相关文献

参考文献23

  • 1Kusaba T,Nakayama T,Yamazumi K,et al.Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. Journal of Clinical Pathology . 2005
  • 2Mora LB,Buettner R,Seigne J,et al.Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Research . 2002
  • 3Yu H,Jove R.The STATs of cancer-new molecular targets come of age. Nature Reviews Cancer . 2004
  • 4Turkson J,Jove RH.STAT proteins: novel molecular targets for cancer drug discovery. Oncegene . 2000
  • 5Freytag S O,Stricker H,Pegg J,et al.Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Research . 2003
  • 6DeWeese TL,van der Poel H,Li S,et al.A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research . 2001
  • 7Nemunaitis J,Ganly I,Khuri F,et al.Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase Ⅱ trial. Cancer Research . 2000
  • 8Mizuguchi H,Hayakawa T.Targeted adenovirus vectors. Human Gene Therapy . 2004
  • 9Han Z,Hong Z,Chen C, et al.A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis . 2009
  • 10Page JG,Tian B,Schweikart K,et al.Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. American Journal of Obstetrics and Gynecology . 2007

二级参考文献162

  • 1Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Statl activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998, 102:1385 - 1392.
  • 2Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcino-genesis in vivo. Proc Natl Acad Sci USA 2000, 97:4227-4232.
  • 3Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998,394:145- 151.
  • 4Gray M J, Zhang J, Ellis LM, et al. HIF- 1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110- 3120.
  • 5Loeffler S, Fayard B, Weis J, Weissenberger J. Intedeukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Spl. IntJ Cancer 2005,115:202-213.
  • 6Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 2001, 28:56-66.
  • 7Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD 1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005,113:109-115.
  • 8Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Group ECO. Phase III randomized trial ofcisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
  • 9Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005, 5:1085-1093.
  • 10Vincent PW, Bridges A J, Dykes D J, et al. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer ChemotherPharmacol 2000, 45:231-238.

共引文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部